A new trading day began on Tuesday, with Nautilus Biotechnology Inc (NASDAQ: NAUT) stock price up 28.22% from the previous day of trading, before settling in for the closing price of $0.72. NAUT’s price has ranged from $0.66 to $3.09 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged -2.50%. With a float of $57.92 million, this company’s outstanding shares have now reached $126.15 million.
In an organization with 155 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Nautilus Biotechnology Inc (NAUT) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Nautilus Biotechnology Inc is 54.08%, while institutional ownership is 29.10%. The most recent insider transaction that took place on May 08 ’25, was worth 8,788. In this transaction Chief Scientist of this company bought 12,000 shares at a rate of $0.73, taking the stock ownership to the 20,491,892 shares. Before that another transaction happened on May 12 ’25, when Company’s Chief Scientist bought 1,500 for $0.73, making the entire transaction worth $1,098. This insider now owns 20,493,392 shares in total.
Nautilus Biotechnology Inc (NAUT) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -2.50% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -5.57% during the next five years compared to -4.55% drop over the previous five years of trading.
Nautilus Biotechnology Inc (NASDAQ: NAUT) Trading Performance Indicators
Here are Nautilus Biotechnology Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 17.36.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.55, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.71 in one year’s time.
Technical Analysis of Nautilus Biotechnology Inc (NAUT)
Let’s dig in a bit further. During the last 5-days, its volume was 0.28 million. That was better than the volume of 0.15 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 62.75%. Additionally, its Average True Range was 0.08.
During the past 100 days, Nautilus Biotechnology Inc’s (NAUT) raw stochastic average was set at 18.41%, which indicates a significant decrease from 76.29% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 116.71% in the past 14 days, which was higher than the 92.83% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.8651, while its 200-day Moving Average is $1.9233. However, in the short run, Nautilus Biotechnology Inc’s stock first resistance to watch stands at $1.0448. Second resistance stands at $1.1626. The third major resistance level sits at $1.3152. If the price goes on to break the first support level at $0.7744, it is likely to go to the next support level at $0.6218. Assuming the price breaks the second support level, the third support level stands at $0.5040.
Nautilus Biotechnology Inc (NASDAQ: NAUT) Key Stats
With a market capitalization of 116.95 million, the company has a total of 126,148K Shares Outstanding. Currently, annual sales are 0 K while annual income is -70,780 K. The company’s previous quarter sales were 0 K while its latest quarter income was -16,610 K.
